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Pulmonary hypertension represents an important cause of morbidity and mortality in
patients with mitral stenosis who undergo cardiac surgery, especially in the postoperative
period. The aim of this study was to test the hypothesis that inhaled nitric oxide (iNO)
would improve the hemodynamic effects and short-term clinical outcomes of patients with
mitral stenosis and severe pulmonary hypertension who undergo cardiac surgery in a
randomized, controlled study. Twenty-nine patients (4 men, 25 women; mean age 46  2
years) were randomly allocated to receive iNO (n  14) or oxygen (n  15) for 48 hours
immediately after surgery. Hemodynamic data, the use of vasoactive drugs, duration of
stay, and short-term complications were assessed. No differences in baseline characteristics
were observed between the groups. After 24 and 48 hours, patients receiving iNO had a
significantly greater increase in cardiac index compared to patients receiving oxygen
(p<0.0001). Pulmonary vascular resistance was also more significantly reduced in patients
receiving iNO versus oxygen (117 dyne/s/cm5, 95% confidence interval 34 to 200, vs
40 dyne/s/cm5, 95% confidence interval 34 to 100, p  0.005) at 48 hours. Patients in the
iNO group used fewer systemic vasoactive drugs (mean 2.1 0.14 vs 2.6 0.16, p 0.046)
and had a shorter intensive care unit stay (median 2 days, interquartile range 0.25, vs
median 3 days, interquartile range 7, p  0.02). In conclusion, iNO immediately after
surgery in patients with mitral stenosis and severe pulmonary hypertension improves
hemodynamics and may have short-term clinical benefits. © 2011 Elsevier Inc.(Am J Cardiol 2011;107:1040–1045)
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Open access under the Elsevier OA license.It has been shown that the pulmonary vasoconstriction
present in clinical pulmonary hypertension can be alleviated
in the short term using inhaled nitric oxide (iNO) through a
mechanism involving vascular smooth muscle relaxation.1
In humans, the ability of iNO to reduce pulmonary vascular
resistance (PVR) while sparing systemic resistance by se-
lective pulmonary vasodilatation has been exploited in
patients with right ventricular dysfunction,2,3 acute lung
injury,4 and lung transplantation.5 Specifically in patients
with mitral stenosis, in whom chronic left-sided underfilling
is prominent, the use of iNO has not been studied thor-
oughly. Most studies were not randomized or controlled  
sed
on the immediate hemodynamic effects of iNO,6 used iNO
during brief periods only,7,8 or were restricted to children9
or women.10 Fattouch et al11 compared the use of iNO in
itral stenosis with inhaled prostacyclin and intravenous
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Open access under the Elsevier OA license.itroprusside but did not include a control group not using
asodilators. This is the first randomized controlled study of
atients with severe mitral stenosis and pulmonary hyper-
ension using iNO compared to a control group receiving
nly oxygen. We observed not only the hemodynamic ef-
ects of each treatment but also the associated short-term
linical outcomes in these patients.
ethods
The study was approved by the institutional research
ommittee, and all subjects gave written informed consent.
atients were consecutively selected at an outpatient cardiac
alve disease clinic of a tertiary cardiology referral hospital.
en and women aged 18 years were selected if they met
ll the following inclusion criteria: mitral stenosis with a
alve area 1.5 cm2; severe pulmonary hypertension, de-
ned as pulmonary artery systolic pressure (PASP) 60
m Hg; and symptomatic disease with New York Heart
ssociation functional class II. Patients were excluded if
hey presented with concomitant valvular disease other than
itral stenosis (specifically moderate or important mitral
egurgitation as defined by preoperative quantitative echo-
ardiography) or had severe left or right ventricular dys-
unction, defined as an ejection fraction 40% by preoper-
tive echocardiography. Nineteen screened patients were
www.ajconline.org
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1041Valvular Heart Disease/Nitric Oxide in Mitral Stenosis Surgeryexcluded before randomization because of concomitant mi-
tral regurgitation (15 patients) or severe left ventricular
dysfunction (3 patients). Central computerized randomiza-
tion of the treatment assignments was performed. Conceal-
ment was interrupted only when the patient was weaned
from cardiopulmonary bypass and started to receive the
designated therapy.
Before surgery, baseline 2-dimensional echocardiogra-
phy and Doppler echocardiography were performed using
commercially available equipment (Sonos 5500; Philips
Medical Systems, Andover, Massachusetts). The ejection
fraction, transmitral valve gradient, valve area calculated
using the pressure half-time method, mitral valve echocar-
diographic score,12 and PASP estimated using the modified
ernoulli equation were determined.
Before anesthesia induction in the operating room, a
ulmonary artery catheter was placed in the right internal
ugular vein or right subclavian vein, and pulmonary capil-
ary wedge pressure, PASP, cardiac output calculated by
hermodilution, and PVR were established. Cardiac output
easurements were obtained from the mean of 3 consecu-
ive end-expiratory readings. Patients were operated on us-
ng standard surgical procedures, and the choice of valve
epair or replacement was left to the surgeons’ discretion.
Immediately before weaning off cardiopulmonary by-
ass, patients randomized to the iNO arm had the NO
elivery equipment attached to the anesthesia breathing
ircuit. The surgical team was not aware of the patient
andomization allocation until this moment. Inhaled NO
as delivered using NO tanks connected to the inspiratory
imb of the airflow tubes at a concentration of 10 ppm, a
ose with the best cost/benefit ratio according to previous
osing studies.13 Concentrations of iNO and NO2 were
measured continuously with a dedicated monitoring device
(NOxBox; Bedfont Instruments, Rochester, United King-
dom). Patients randomized to the oxygen control group
continued to receive standard anesthesia care to maintain
oxygen saturation 95%.
All patients were then transferred to a surgical intensive
care unit (ICU) and continued the assigned treatment for up
to 48 hours, in the ICU or in the ward. The criteria for ICU
discharge were prespecified as hemodynamic stability (de-
fined by a mean systemic arterial pressure 65 mm Hg),
mechanical ventilation weaning with no signs of respiratory
distress (as evaluated by the attending physician, who was
blind to the outcomes of the study), urinary output 0.5
ml/kg/hour, and no significant bleeding from surgical sites.
No patient was held in the ICU because of the protocol if he
or she was considered apt for discharge and achieved the
mentioned criteria. After extubation, patients received iNO
or oxygen through a facial mask, keeping the aforemen-
tioned parameters. In all patients, an airtight sealed nonre-
breathing cushioned face mask was used, allowing mini-
mum leakage of either iNO or oxygen. Inhaled NO
concentration was measured through a sampling line adja-
cent to the mask to guarantee a precise reading of the
delivered concentration.
The use of any vasoactive drugs was permitted through-
out the study and was left to the choice of the attending
physician in the ICU, blinded to the outcomes of the study.
At 24 and 48 hours after the initiation of iNO or controloxygen, a new reading of the pulmonary artery catheter was
carried out, with the determination of the same parameters
obtained before surgery. After 48 hours, patients withdrew
oxygen therapy unless contraindicated by the assisting phy-
sician. Patients receiving iNO were progressively weaned,
with total switch to room air or oxygen by mask as needed
in 1 hour. All patients were followed during the total hos-
pital stay for the assessment of predefined complications
(acute renal insufficiency, infections, need for reintubation,
liver failure, and death).
The primary outcomes of this study were the differences
at 48 hours compared to the baseline cardiac index and PVR
in each treatment group. These primary end points were
chosen to allow a more accurate sample size calculation as
well as to provide a more relevant link to the clinical effects.
Secondary outcomes included clinical variables regarding
postoperative complications, total days in the ICU, total
hospital stay, and number and dosing of systemic intrave-
nous vasoactive drugs. Complications were defined as acute
renal insufficiency (renal output 0.3 ml/kg/hour), need for
reintubation, sepsis according to standardized definitions,14
cardiogenic shock, and need for urgent reoperation.
Data are presented as mean  SD, except for total
hospital and ICU length of stay, which were not normally
distributed and are presented as median and interquartile
range. Comparisons among absolute values of the hemody-
Table 1
Baseline characteristics
iNO Oxygen
ariable (n  14) (n  15) p Value
Age (years) 48  11 44  13 0.43
Women 13 (93%) 12 (80%) 0.60
Body mass index (kg/m2) 23  4 22 4 0.69
New York Heart Association
functional class
0.39
II 3 (21%) 6 (40%)
III 10 (72%) 7 (47%)
IV 1 (7%) 2 (13%)
Atrial fibrillation 8 (57%) 8 (53%) 0.99
Left ventricular ejection
fraction (%)
71  8 70 6 0.48
Mitral valve echocardiographic
score
10.1  1.7 10.6  1.0 0.55
Mitral valve area (cm2) 0.92  0.18 0.85  0.21 0.35
Mitral valve mean diastolic
gradient (mm Hg)
14.9  3.7 16.4  5.8 0.48
PASP (echocardiography)
(mm Hg)
80  21 80  17 0.71
Pulmonary capillary wedge
pressure (mm Hg)
26.3  10.5 27.9  10.5 0.87
PASP (pulmonary artery
catheterization) (mm Hg)
73  10 73  14 0.99
Cardiac index (L/min/m2) 2.35  0.6 2.89  0.9 0.10
PVR (dyne/s/cm5) 341  183 264  133 0.38
ypass time (minutes) 88 31 94  34 0.59
alve replacement 6 (43%) 3 (20%) 0.25
eoperation 4 (29%) 3 (20%) 0.91
ntensive care unit stay (days) 2.0 (0.25) 3.0 (7.0) 0.02
Data are expressed as mean  SD, number (percentage), or median
interquartile range).namic parameters preoperatively and at 24 and 48 hours
01042 The American Journal of Cardiology (www.ajconline.org)Figure 1. Values of pulmonary capillary wedge pressure, PASP, cardiac index, and PVR in patients using iNO (black circles) versus oxygen (black squares)
preoperatively and at 24 and 48 hours after surgery. There was a significant decrease in PVR at 48 hours in patients using iNO compared to oxygen. *p 
.005.Figure 2. Changes compared to baseline of hemodynamic data in patients using oxygen (white bars) and iNO (black bars). Cardiac index increased much
more significantly in patients receiving iNO at 24 and 48 hours (p 0.01 for both) compared to preoperative values.
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1043Valvular Heart Disease/Nitric Oxide in Mitral Stenosis Surgerywere done using analysis of variance for repeated measures
on ranks with Tukey’s and profile tests for time and group
differences. Analyses of the differences as well as other
comparisons regarding the iNO and control groups were
made using unpaired Student’s t tests for continuous vari-
ables, Mann-Whitney or chi-square tests for proportions,
and Fisher’s exact tests as needed. Sample size was calcu-
lated on the basis of an  error of 0.05 and power of 80%
to detect a 40% difference in PVR between the 2 groups.
We calculated the number of subjects needed for the study
to be 30 (15 in each group) on the basis of previous stud-
ies.10 All calculations were done using intention-to-treat
nalysis and were performed in SAS version 9.1.3 (SAS
nstitute Inc., Cary, North Carolina). Significance was as-
umed at a 2-tailed p value 0.05.
esults
Twenty-nine patients (86% women, mean age 46  2
years) were enrolled in the study, with a total evaluation of
48 patients. One patient withdrew consent on the morning of
the surgery and was not included in the final analysis. The
baseline clinical characteristics of the 2 groups are listed in
Table 1. No significant differences between the groups were
observed. Patients enrolled were characterized by signifi-
cant mitral stenosis (mean valve area 0.89 0.04 cm2) with
evere pulmonary hypertension (mean PASP 73  3 mm
g, mean PVR 303  31 dyne/s/cm5). Only 1 death oc-
curred; a patient in the oxygen group died 22 days after
surgery with sepsis and multiple-organ failure. All random-
ized patients received the assigned treatment with iNO or
oxygen during the full duration of the planned intervention,
with no crossovers. Patients in the iNO group were mechan-
ically ventilated for 7.5  8.5 hours, while patients receiv-
ng oxygen were ventilated for 15.1  21.8 hours (p 
.23). No patient developed significant mitral valve regur-
itation as assessed by echocardiography 7 days after sur-
ery (data not shown).
Changes in hemodynamic parameters after surgery are
resented in Figures 1 and 2. After 24 and 48 hours, the 2
roups had significant reductions in pulmonary capillary
edge pressure, with no differences between patients re-
eiving iNO or oxygen. Significant decreases also occurred
n PASP at 24 and 48 hours compared to that at baseline in
he 2 groups, with no differences between them. However,
he cardiac index increased significantly in patients receiv-
ng iNO at 24 and 48 hours (p0.0001 for both). Moreover,
lthough the cardiac index increased significantly compared
o that at baseline in the 2 groups after 24 hours, this
ncrease was sustained at 48 hours only in patients who
eceived iNO, with a mean increase of 1.58 L/min/m2 (95%
onfidence interval [CI] 1.0 to 2.16, p 0.0001) versus 0.4
/min/m2 (95% CI 0.01 to 0.82, p  0.06) in patients
eceiving oxygen. PVR changes compared to those at base-
ine were also observed only in the group with iNO at 24
ours (103 dyne/s/cm5, 95% CI 14 to 192, p  0.04)
and 48 hours (117 dyne/s/cm5, 95% CI34 to200, p
0.02), with significant differences between the 2 groups at
48 hours (p  0.005). Partial pressure of oxygen was not
significantly different between the groups at baseline or at
24 and 48 hours (baseline iNO group 92  7 vs 93  9 mmHg in the oxygen group, p  0.90; 24 hours 190  72 vs
221  97 mm Hg, p  0.40; 48 hours 158  67 vs 193 
02 mm Hg, p  0.50). Although we did not invasively
monitor the hemodynamic status of patients after weaning
of iNO or oxygen, no patient in the study experienced any
clinically relevant hemodynamic symptoms after with-
drawal of either therapy.
Patients who received iNO had significantly shorter ICU
stays compared to patients who received oxygen (Table 1).
However, total hospital stay was similar in the 2 groups
(median 10 days, interquartile range 6.0 in iNO group vs
median 13 days, interquartile range 16.25 in the oxygen
group, p  0.14).
The use of concurrent vasoactive drugs might have in-
terfered with the results regarding the previous hemody-
namic measurements. Table 2 lists systemic intravenous
vasoactive drugs used in the 2 groups during ICU and
hospital stay. Although no significant differences were ob-
served regarding the percentage of patients using each drug
or the maximum dose used in each patient, the mean number
of systemic vasoactive drugs used during hospital stay was
significantly smaller in the iNO group (2.1  0.14) com-
pared to that in patients receiving only oxygen (2.6  0.16)
(p 0.046). There were a nonsignificant smaller proportion
of patients receiving nitroprusside and milrinone in the iNO
group compared to controls. Other drugs known to signifi-
cantly affect pulmonary pressure were not used by any
patient in our study either during ICU or ward stay.
The percentage of patients with any of the predefined
complications was similar in the 2 groups (9 of 15 [60%] in
the oxygen group vs 4 of 14 [29%] in the iNO group, p 
0.14). According to the definitions of complications previ-
ously mentioned, 3 patients in the iNO group needed urgent
reoperation due to bleeding complications (1 for cardiac
tamponade and 2 for 500 ml of sanguineous drainage in
the first hour postoperatively), and 1 patient developed
sepsis. In the oxygen group, 2 patients needed reintubation,
Table 2
Concurrent vasoactive drugs used in each group during intensive care
unit and hospital stay
iNO Oxygen
rug (n14) (n15) p Value
obutamine
Percentage of patients 86% 87% 0.90
Maximum dose (g/kg/min) 7.7  3.8 8.7  4.9 0.37
Nitroprusside
Percentage of patients 43% 73% 0.08
Maximum dose (g/kg/min) 0.68  0.67 0.86  1.39 0.49
Dopamine
Percentage of patients 21% 27% 0.37
Maximum dose (g/kg/min) 4.2  1.5 6.7  1.4 0.99
Norepinephrine
Percentage of patients 14% 40% 0.28
Maximum dose (g/min) 1.77  0.4 2.55  4.7 0.19
Milrinone
Percentage of patients 29% 60% 0.06
Maximum dose (g/kg/min) 0.15  0.28 0.29  0.32 0.14
Maximum number of systemic
vasoactive drugs used
2.1  0.14 2.6  0.16 0.0462 patients underwent urgent reoperation (1 for cardiac tam-
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1044 The American Journal of Cardiology (www.ajconline.org)ponade and 1 for high blood drainage), 1 patient developed
acute renal failure, and 4 patients were diagnosed with
sepsis. Although we did not find any significant differences
between the groups regarding complications, we could de-
termine that patients who presented with complications after
surgery had significantly fewer change in PVR values com-
pared to patients with no complications at 24 and 48 hours.
The mean change in PVR in patients with complications
was 4 42 dyne/s/cm5 compared to124 34 dyne/s/cm5
in patients with no complications at 24 hours (p 0.02) and
31  41 and 98  37 dyne/s/cm5, respectively, at 48
ours (p  0.03).
iscussion
We have demonstrated that treatment with iNO immedi-
tely after surgery in patients with significant mitral stenosis
nd severe pulmonary hypertension is associated with in-
reased cardiac output and reduced PVR. This in turn trans-
ated into shorter ICU stays and less need for systemic
asoactive drug use.
Different therapies for the postoperative management of
ulmonary hypertension are available and include intrave-
ous nitroprusside, inhaled prostacyclin, and intravenous
hosphodiesterase inhibitors.15 In contrast with these ther-
apies, iNO is rapidly inactivated through a hemoglobin-
mediated process while still in the pulmonary circulation,16
with clinical studies showing no effect on systemic circu-
lation17,18 and an established safety profile even up to 40
pm.19 In our patients, also not statistically significant, there
as a smaller proportion of patients in the iNO group
eceiving nitroprusside as well as milrinone, and no differ-
nces were found in the use of other systemic vasoactive
rugs. This reinforces the benefits of iNO use, because these
atients exhibited a significant decrease in PVR while us-
ng, at most, the same doses of vasoactive drugs.
In our study, we chose to use a dose of 10 ppm of iNO
o further minimize any toxic risks associated with the drug
nd due to previous dose-response studies showing no ben-
fits of increased doses.13 The 34% reduction in PVR seen
n patients using iNO is in accordance with previous reports
ndicating reductions of PVR up to 27% to 45% with iNO,
ith more significant reductions being obtained with 20
han at 10 ppm.7,8,20 We also observed an increase in car-
iac output after surgery in the 2 groups, but the increase
ith iNO was significantly greater and sustained. This find-
ng has also been reported by others but was not reproduced
n all iNO studies.10,21 This apparent discrepancy can be
attributed to differences in preoperative cardiac function or
hemodynamic conditions, all of which might influence the
final cardiac output observed with the treatment. In fact, in
the presence of ventricular dysfunction, an increase in left
atrial end-diastolic pressure with increased pulmonary
blood flow with iNO may lead to pulmonary edema and
reduced cardiac output.22 It is also interesting to point out
that despite the reductions in pulmonary hypertension ob-
served in the study, the values of the mean PASP were still
elevated in the 2 groups. Part of this is due to the vast and
complex pathophysiology of pulmonary hypertension, in
which a variety of arterial abnormalities play a role at
different stages in the same patient.23 Therefore, acute in-erventions in the postoperative setting may revert only part
f the functional and structural changes represented by
ntimal hyperplasia, medial hypertrophy, adventitial prolif-
ration, thrombosis, and inflammation.
The increase in cardiac output and reduced PVR ob-
erved in the iNO group in this study was associated with an
mprovement in several clinical parameters that may result
n improved management of these patients after surgery.
irst, the total ICU stay was reduced using iNO, a finding
lso reported by others recently.11 We also found that the
se of iNO permitted a more judicious use of systemic
asoactive drugs, with a better hemodynamic profile in
hese patients despite the use of a reduced number of these
gents. Interestingly, a trend was noted toward fewer com-
lications in patients receiving iNO compared to controls,
ith a shorter total hospital stay. Patients with no compli-
ations had significantly higher reductions in PVR postop-
ratively than did patients presenting with any complica-
ions. This may reflect the baseline reversibility of
ulmonary hypertension in these patients, but the role of
NO in this reduction cannot be disregarded. Moreover,
atients enrolled in this study represented a very high risk
opulation, with a mean PASP of 73  3 mm Hg, much
igher than the 39 to 61 mm Hg reported in other stud-
es.7,8,24,25 Therefore, any degree of reduction in PVR that
would mitigate complications in these patients would be
desirable.
Limitations of this study include the hemodynamic read-
ings at 24 and 48 hours in the ICU setting, while the patients
were taking other vasoactive drugs that might have con-
founded our results, although no significant differences
were observed in terms of frequency and maximum doses of
these drugs in the 2 groups. The use of right ventricular
parameters as outcomes of the study would also have en-
hanced our results, but we believe that other variables stud-
ied already give independent and prognostic information
regarding the right-sided cardiac chambers to allow the
conclusions presented here. Last, although it could be de-
sirable to blind the effective treatment, because we needed
to monitor the values of NO2 for safety reasons, this ap-
roach would not seem possible.
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